Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-03-15
2011-03-15
Havlin, Robert (Department: 1626)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C548S950000
Reexamination Certificate
active
07906652
ABSTRACT:
Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, Alzheimer's disease, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, cirrhosis of the liver, non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH).
REFERENCES:
patent: 4052383 (1977-10-01), Gold et al.
patent: 4133881 (1979-01-01), Cale et al.
patent: 4242261 (1980-12-01), Cale
patent: 6355631 (2002-03-01), Achard et al.
patent: 6479479 (2002-11-01), Achard et al.
patent: 6518264 (2003-02-01), Achard et al.
patent: 6858603 (2005-02-01), Achard et al.
patent: 6872717 (2005-03-01), Achard et al.
patent: 7132414 (2006-11-01), Achard et al.
patent: 2002/0016337 (2002-02-01), Cuny et al.
patent: 2003/0055033 (2003-03-01), Achard et al.
patent: 2006/0270650 (2006-11-01), MacNeil et al.
patent: 2006/0293299 (2006-12-01), Baker et al.
patent: 2007/0066587 (2007-03-01), Altisen et al.
patent: 1328269 (2004-05-01), None
patent: WO 97/46511 (1997-12-01), None
patent: WO 99/04794 (1999-02-01), None
patent: WO 00/15609 (2000-03-01), None
patent: WO 00/71518 (2000-11-01), None
patent: WO 01/64632 (2001-09-01), None
patent: WO 01/64633 (2001-09-01), None
patent: WO 01/64634 (2001-09-01), None
patent: WO 01/64676 (2001-09-01), None
patent: WO 02/12187 (2002-02-01), None
patent: WO 03/007939 (2003-01-01), None
patent: WO 03/018060 (2003-03-01), None
patent: WO 03/020314 (2003-03-01), None
patent: WO 2004/056800 (2004-07-01), None
patent: WO 2004/096763 (2004-11-01), None
patent: WO 2004/096794 (2004-11-01), None
patent: WO 2005/000809 (2005-01-01), None
patent: WO 2005/077897 (2005-08-01), None
patent: WO 2006/119260 (2006-11-01), None
patent: WO 2007/062193 (2007-05-01), None
patent: 2007067617 (2007-06-01), None
patent: 2007142217 (2007-12-01), None
Kubinyi (3D QSAR in Drug Design: Ligand-Protein Interactions and Molecular Similarity, vol. 2-3, Springer, 1998, 800 pages). TOC and pp. 243-244 provided.
Byrn et al., Pharm. Res., v. 12, n. 7, p. 945-54, 1995.
Land and Kruse (Drug Discovery Today, (2005), v. 10, n. 10, p. 693-702).
Wiley et al. (J. Pharmacology and Exper. Therap., (2001), v. 296, n. 3, p. 1013-1022).
Adam et al., Exp. Opin. Ther. Patents, vol. 12 (2002), pp. 1475-1489, “Recent advances in the cannabinoids”.
Lange et al., Drug Discovery Today, vol. 10 (2005), p. 693-702, “Medicinal chemistry strategies to CB1 cannabinoid receptor antagonists”.
Hillier, “A one-pot preparation of 1,3-disubstituted azetidines”, J. Org. Chem. (2006), 7885-7887, vol. 71.
Baker Robert K.
Hale Jeffrey J.
Miao Shouwu
Rupprecht Kathleen M.
Brown Baerbel R.
Havlin Robert
Merck Sharp & Dohme Corp.
Todaro John C.
LandOfFree
Heterocycle-substituted 3-alkyl azetidine derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heterocycle-substituted 3-alkyl azetidine derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocycle-substituted 3-alkyl azetidine derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2702967